MedTrace Logo

Evaluating the Safety of the SPECTRALIS CENTAURUS Device

NCT04968756 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-01-11

No results posted yet for this study

Summary

The objective of this clinical trial is to evaluate the safety of the SPECTRALIS CENTAURUS device (HuCE-optoLab, BFH TI, Biel, CH) in a clinical setting on patients with retinal diseases.

Conditions

Interventions

DEVICE

Selective retina therapy SPECTRALIS CENTAURUS device

Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device

Sponsors & Collaborators

  • Bern University of Applied Sciences

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Chantal Dysli, MD PhD · University of Bern

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04968756 on ClinicalTrials.gov